Kornimate/medical-research-clean huggingface dataset:
detection of urinary stones on uldct with deep-learning image reconstruction algorithm

Conditions: Urolithiasis; Urinary Tract Stones; Renal Colic; Deep Learning Reconstruction

Summary: urolithiasis has an increasing incidence and prevalence worldwide, and some patients may have multiple recurrences. because these stone-related episodes may lead to multiple diagnostic examinations requiring ionizing radiation, urolithiasis is a natural target for dose reduction efforts. abdominopelvic low dose ct, which has the highest sensitivity and specificity among available imaging modalities, is the most appropriate diagnostic exam for this pathology. the main objective of this study is to evaluate the diagnostic performance of ultra-low dose ct using deep learning-based reconstruction in urolithiasis patients.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old, * patient referred for abdominopelvic ct to confirm urolithiasis or for follow-up, * affiliation to a social security program, * ability of the subject to understand and express opposition exclusion criteria: * age \<18 years old, * person under guardianship or curators, * pregnant woman, * any contraindications to ct

Keywords: urolithiasis urinary tract stones renal colic deep learning reconstruction radiation dose dose reduction low dose ct
physical activity for a long and healthy life

Conditions: Overweight; Insulin Resistance; Diabetes Mellitus, Type 2

Summary: the aim of the study is to 1) delineate the molecular mechanisms behind the large variation in insulin sensitivity among apparently healthy subjects and to 2) establish the dose-response relationship between physical training and a) metabolic health, b) appetite and c) cultural health.


Eligibility criteria:
inclusion criteria: * healthy according to interview * caucasian * sedentary, vo2max \< 45 ml/kg/min * bmi 25-30 kg/m2 * fat percentage 25% \< * weight stable (+/- 2 kg within past 6 months) exclusion criteria: * first degree relatives with type 2 diabetes * hemoglobin concentration \< 8 mmol/l * fasting plasma glucose 6.1 mmol/l \< * blood pressure 140/90 mmhg \< * regular intake of medicine

Keywords: exercise
double blind randomized, monocentric, cross-over, placebo-controlled study to evaluate the effect of citalopram on motivation

Conditions: Normal Volunteers

Summary: the aim of the current study is to examine the role of serotonin on the cognitive parameters of motivation. they are embedded in a conceptual framework of motivation that merges decision-making and reinforcement learning theories. every action is conceived as path from one state to another. the different states are associated to different values (positive for rewards and negative for punishments), and the different actions to different costs (risk, effort and delay). the tasks are designed such that the sensitivity to the state and action parameters can be inferred by fitting computational models.the primary objective is to characterize the effect of citalopram 30mg on reward sensitivity, assessed in an incentive force task, in which participants are asked to squeeze a hand grip to win monetary rewards. secondary objectives are to characterize the effect of citalopram 30mg on other cognitive parameters of motivation (assessed with a motivational battery that includes rating, choice and learning tasks).


Eligibility criteria:
inclusion criteria: * man or woman, age ≥ 18 and \< 50 * weight between 50 kg and 90 kg. * no contraindication to effort * no evolutive pathology that could interfere with the current study signed consent * medical insurance ("sécurité sociale") exclusion criteria: * age \ 50 * smokers * person under curatorship, or guardianship, or with civil rights deprivation * history of neurologic or psychiatric pathology * presence of any psychotropic treatment * chronic or actual consumption of alcohol, or psychotropic drugs * pregnancy, breastfeeding * woman of childbearing potential without effective contraception * hypersensitivity to atomoxetine or other constituents of the product * pheochromocytoma * narrow angle glaucoma * liver failure * severe cardiovascular disorders * severe cerebrovascular discorders * treatment with non-selective monoamine oxidase inhibitor (maoi) : iproniazide. * treatment with linezoline, lithium, milleperthuis, tramadol, tryptans. * treatment with pimozide, or treatment that can induce a qt prolongation (neuroleptics, class ia and iii antiarrythmic, moxifloxacine, erythromicine, methadone, mefloquine, tricyclic antidepressants, lithium, cisapride), or treatment that can induce an hydroelectrolytic inbalance (thiazide diuretics). * treatment with anticoagulants * treatment that can decrease seizure threshold: antidepressants, neuroleptics, mefloquine, buproprione, tramadol * enzyme inducers, (rifampicine, ...) * treatment that can interfere with the performance of the subject: beta2 adrenergic agonists, analgesics, corticosteroïds, anti-inflammatory drugs, ...
effects of the myofascial arm pull with and without active release technique in adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: the aim of the study is to determine the effects of the myofascial arm pull with and without active release technique on pain, rom and disability in adhesive capsulitis.

adhesive capsulitis (frozen shoulder), a painful disorder caused by capsular inflammation that results in fibrosis and rigidity of the glenohumeral joint capsule, is characterized by a progressive loss of both active and passive glenohumeral movements. frozen shoulder can be primary (also known as idiopathic) if there is no underlying cause of disease or it can be secondary. the term "secondary frozen shoulder" is associated with injury, trauma, cardiovascular diseases, hemiparesis, or diabetes.active release technique and myofascial arm pull technique are both effective treatment options for patients with adhesive capsulitis. these techniques help to improve range of motion and reduce pain by releasing tension and adhesions in the affected area. active release technique focuses on releasing tension and adhesions in the soft tissues surrounding the affected joint, while the myofascial arm pull technique aims to improve range of motion by stretching the muscle and fascia in the affected area. by incorporating these techniques into a comprehensive treatment plan, patients of adhesive capsulitis can see significant improvement in their pain, range of motion and disability. because the method of treatment is inexpensive, findings of this study could be beneficial in revision of the clinical protocols to manage the patients of adhesive capsulitis.

Eligibility criteria:
inclusion criteria: * both male and female; mean age (35-60). * case diagnosed with adhesive capsulitis, both primary and secondary origin. * freezing stage of adhesive capsulitis. * those with at least a 50% reduction in the range of motion (rom). exclusion criteria: * history of shoulder surgery or manipulation under anesthesia, local corticosteroid injection administration to the affected shoulder within the last 3 months. * neurological deficit affecting the shoulder functioning during daily activities. * pathology of the shoulder joint other than adhesive capsulitis. * pain or disorder of the cervical spine, elbow, wrist or hand. * patients diagnosed with cancer

Keywords: adhesive capsulitis active release technique myofacial arm pull technique pain range of motion
seroquel therapy for substance use disorders comorbid with schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder; Substance Abuse; Substance Dependence

Summary: it is hypothesized that the atypical antipsychotic, seroquel, will cause significant reduction in drug and alcohol cravings in patients with schizophrenia and comorbid cocaine and/methamphetamine dependence compared to the atypical antipsychotic, risperidone (risperdal). patients treated with seroquel will have less use of cocaine and/or methamphetamine as measured by the time line follow-back, over a 24-week follow-up period.

schizophrenia is a serious mental illness that afflicts approximately 1% of the population (1). often these patients have comorbid cocaine and amphetamine dependence, which increases the severity of psychotic symptoms associated with schizophrenia, decreases treatment compliance and worsens prognosis. the treatment of schizophrenia with comorbid cocaine and/or amphetamine dependence is complex and involves adherence to psychiatric medications, most often antipsychotic agents, along with participation in specific substance abuse treatment such as structured living, attendance at self-help group meetings, individual and group therapy and a commitment to sobriety. in the absence of specific pharmacotherapy of cocaine and amphetamine dependence, various antipsychotic medications have been compared to see if they impact comorbid cocaine and amphetamine abuse in addition to their antipsychotic effects. the primary objective of this study is to test whether seroquel as a mono-therapy decreases cocaine and/or methamphetamine use in patients with schizophrenia as compared to risperidone.

Eligibility criteria:
inclusion criteria: 1. ages 19 - 65. 2. diagnosis of schizophrenia or schizoaffective disorder with comorbid cocaine and/or amphetamine abuse/dependence as confirmed by structured clinical interview for dsm-iv. 3. comorbid diagnoses of depression, anxiety and/or personality disorders are permitted. 4. ability to provide signed informed consent. 5. stable general medical health. exclusion criteria: 1. dangerous to self or others. 2. pregnancy, inability or unwillingness to use approved methods of birth control. 3. inability or unwillingness to provide signed informed consent. 4. diagnosis of bipolar disorder, primary major depressive disorder (as major axis i diagnosis). 5. inability to attend outpatient research clinic. 6. medical conditions, which would preclude use of seroquel. 7. absolute need for ongoing treatment with antipsychotic other than seroquel. 8. medical instability defined as likelihood of needing to change prescription medication during the course of the study. 9. patients currently taking quetiapine or risperidone. 10. patients with unsuccessful treatment with quetiapine or risperidone. 11. subjects with a ham-d score of ≥20 at screening.

Keywords: cocaine abuse cocaine dependence amphetamine abuse amphetamine dependence schizophrenia comorbid schizoaffective disorder
quantitative mri for functional assessment following sbrt for spinal metastases

Conditions: Spinal Metastases

Summary: the purpose of this study is to determine if quantitative magnetic resonance imaging (qmri) can objectively measure changes in the tumor/vertebral body and adjacent spinal cord following stereotactic body radiation therapy (sbrt) for painful metastatic spine disease.

metastatic spine disease (msd) can result in considerable morbidity from pain, spinal cord compromise and neurologic disability. recent developments in image-guidance and immobilization have enabled more accurate target localization, which allows methods of precise high-dose radiation delivery such as stereotactic body radiation therapy (sbrt). sbrt carries potential risks of radiation induced myelopathy (rim) and vertebral compression fracture (vcf). magnetic resonance imaging (mri) is a sensitive imaging modality that may be able to detect radiation-induced damage in the vertebral body or spinal cord following sbrt. quantitative mr-based imaging methods may also help to quantify treatment response and help predict subsequent outcomes such as tumor control and vcf risk.

Eligibility criteria:
inclusion criteria: * a diagnosis of metastatic cancer with a vertebral body metastasis or contiguous vertebral body metastases for which sbrt is appropriate * age ≥ 18 years of age * kps ≥ 70 * life expectancy of at least 3 months * no contraindication to undergoing mr imaging * women of childbearing age must have a negative urine or serum pregnancy test to meet eligibility per duke policy * pre-treatment pain score of at least 1/10 based on the numeric pain rating scale (nprs) * disease located from c1 to s5 * subjects with prior radiation to the involved vertebral body are allowed. exclusion criteria: * subjects unable to undergo mri (includes non-mri compatible material or devices and severe claustrophobia) * subjects with prior procedural intervention to the involved vertebral body that would result in artifact (kyphoplasty, screw and/or rod placement); minimally invasive surgery without instrumentation of the involved vertebral body and instrumentation immediately above or below the index lesion is allowed. * subjects with spinal cord compression; minimally invasive "separation" surgery to first resect the epidural component is allowed * pregnant or breast-feeding women * allergy to standard iv contrast agents used in mri * subjects with egfr \<30 30 ml/min2 or on dialysis

Keywords: vertebral compression fracture radiation induced myelopathy
interval training and parkinson's disease

Conditions: Other Disorders of Autonomic Nervous System

Summary: this research is designed to compare the impact of high-intensity interval training and high-velocity circuit resistance training on heart rate variability, gait, and functional performance in patients with parkinsons disease.


Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of parkinson's disease 2. between the ages of 30-90 years of age; 3. movement disorder society-unified parkinson's disease rating scale ≤2, which will be provided by the participant's medical provider and be evaluated within 1 year of the study's inception. exclusion criteria: 1. uncontrolled cardiovascular disease that prevents participation in a training program 2. documented hiv infection or another immunodeficiency syndrome 3. other neuromuscular diseases besides parkinson's disease 4. current musculoskeletal injury that prevents exercise. 5. having a pacemaker or other internal medical devices

Keywords: interval training resistance training
hypomemylating agents combination with edc therapy for elderly patients with myelodysplastic syndrome

Conditions: Myelodysplastic Syndromes; Dendritic Cell; Hypomethylating Agents; Immunotherapy

Summary: the purpose of this study is to optimize the traditional treatment scheme and explore the cure scheme for the elderly by combining the existing mature treatment technology. the primary aim of this innovative immunotherapy using wt1/htert/survivin-loaded dcs is to determine whether this novel dc vaccination is safe and can significantly prevent clinical relapse and increase survival of mds patients.

objective myelodysplastic syndrome (myelodysplasticsyndromes,mds) is a highly age-related malignant clonal disease of the hematological system, which is characterized by pancytopenia and transformation to leukemia. in china, the median age of onset of mds is 70 years old, and the incidence increases with age. it is the most common malignant tumor in the elderly, which seriously threatens the health and survival of the elderly. the 3-year survival rate of traditional combination chemotherapy or demethylation therapy is less than 20%.

Eligibility criteria:
inclusion criteria: 1. elderly mds patients; 2. aged more than 60 years old, general condition, ecog score less than 1; 3. normal function of heart, liver and kidney, serum bilirubin ≤ 35 umol / l; serum creatinine ≤ 150 umol / l; 4. patients are unsuitable or unwilling to receive hematopoietic stem cell transplantation; 5. subjects sign informed consent. exclusion criteria: 1. serious infection was not controlled before treatment; 2. contraindications for the use of dexitabine and azacytidine; 3. other cases that did not meet the admission criteria.
three-dimensional (3d) rectal water contrast transvaginal ultrasonography versus computed colonography in the diagnosis of rectosigmoid endometriosis

Conditions: Endometriosis, Sigmoid; Endometriosis, Rectum

Summary: rectosigmoid involvement by endometriosis causes intestinal symptoms such as constipation, diarrhea, and dyschezia. a non-invasive diagnosis of bowel endometriosis is relevant to provide the patients information on the potential hormonal or surgical treatments. the objective of the current study was to compare the performance of three-dimensional rectal water contrast transvaginal ultrasonography (3d-rwc-tvs) and computed colonography (ctc) in predicting the presence and characteristics of rectosigmoid endometriosis.


Eligibility criteria:
inclusion criteria: - pain and intestinal symptoms suggestive of rectosigmoid endometriosis exclusion criteria: * previous surgical diagnosis of intestinal endometriosis * previous radiological diagnosis of intestinal endometriosis (based on magnetic resonance or double-contrast barium enema * history of colorectal surgery (except appendectomy) * contraindications to bowel preparation or computed colonography (such as non-- compliant patients and rectal malformations) * previous bilateral ovariectomy * psychiatric disorders

Keywords: rectosigmoid endometriosis
td-6450 mad study in hcv infected subjects

Conditions: Hepatitis C; HCV

Summary: this proof of concept study is designed to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of td-6450 in treatment naïve subjects with gt-1, gt-2 or gt-3 chronic hcv.


Eligibility criteria:
inclusion criteria: * subject is hcv antibody positive * subject is treatment naïve, with no history of exposure (single or multiple dose) to interferon, ribavirin or direct acting antivirals. * subject has had a liver biopsy within 3 years or fibroscan evaluation within 6 months prior to screening that clearly excludes cirrhosis. if not available prior to screening, the absence of cirrhosis must be confirmed prior to subject enrollment using either fibroscan or fibrosure®. * subject is negative for hepatitis a (hav), hepatitis b (hbv), and human immunodeficiency virus (hiv). exclusion criteria: * subject has prior histological evidence of cirrhosis or current clinical evidence of cirrhosis in the opinion of the investigator. * subject has a history or evidence of non-hepatitis c chronic liver disease. * subject has an estimated creatinine clearance of \ 60 years of age, calculated using the cockcroft-gault equation.

Keywords: hepatitis c hcv
study to evaluate sepofarsen in subjects with leber congenital amaurosis (lca) type 10 (hyperion)

Conditions: Leber Congenital Amaurosis 10; Blindness; Leber Congenital Amaurosis; Sensation Disorders; Vision Disorder; Neurological Manifestations; Eye Diseases, Hereditary; Eye Diseases; Eye Disorders Congenital; Retinal Disease

Summary: the purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of sepofarsen in subjects with leber congenital amaurosis (lca) due to the c.2991+1655a\>g (p.cys998x) mutation in the cep290.

this is a double-masked, randomized, placebo-controlled, paired-eye study in which one eye of each subject will serve as a control. at the start of the study the two eyes of each subject will be randomized such that one eye receives sepofarsen and the other eye receives placebo for the first year. in the second year, for all subjects, the eye that was randomized to receive sepofarsen will continue to receive sepofarsen. for the eye that was randomized to placebo in the first year, treatment in the second year will be allocated, as follows: 50% of the eyes will continue to receive placebo, and 50% of the eyes will receive sepofarsen. sepofarsen and placebo will be administered via intravitreal injection every 6 months.

Eligibility criteria:
inclusion criteria: 1. confirmed clinical diagnosis of lca10 and a molecular diagnosis of homozygosity or compound heterozygosity for the c.2991+1655a\>g mutation in cep290. 2. adults: \>=18 years / minors: 6 to \<18 years. 3. bcva (fract) equal to or worse than logmar +0.4 (approximate snellen equivalent 20/50) to +2.9 logmar based on quantifiable, reliable fract. lp subjects with documented evidence of prior better vision eligible. 4. symmetrical disease between the two eyes as defined by a bcva (fract) within 0.2 logmar at baseline. 5. detectable onl in the macular area as determined by the crc at screening. exclusion criteria: 1. mutations in genes other than the cep290 gene associated with other ird diseases or syndromes. 2. presence of any ocular pathology in either eye that may make comparison of the eyes not feasible. 3. presence of unstable concurrent cme, or subject started on (or changed dose of) topical or systemic carbonic anhydrase inhibitor treatment in the 3 months prior to enrollment. cme is allowed if stable for 3 months (with or without treatment). 4. presence of any clinically significant lens opacities/cataracts based on the areds lens grading scale. 5. any prior receipt of genetic or stem-cell therapy for ocular or non-ocular disease.

Keywords: lca10 p.cys998x antisense oligonucleotides rna therapy qr-110 sepofarsen cep290 leber's congenital amaurosis c.2991+1655a&gt;g
the effect of zolpidem on outcomes following lumbar spine fusion

Conditions: Spine Fusion; Lumbar Spine Degeneration; Pain, Postoperative; Lumbar Spine Spondylosis

Summary: the purpose of this study is to evaluate if peri-operative zolpidem for posterior lumbar spinal fusion improves patient reported outcomes following surgery.

patients who are undergoing one- to three-level spinal fusion for degenerative lumbar disease will be recruited. they will be randomized to either receive zolpidem or placebo two days preoperatively and five days postoperatively.

Eligibility criteria:
inclusion criteria: * degenerative lumbar disease * age of 18-75 * undergoing open primary one- to three-level lumbar fusion exclusion criteria: * currently use a sleep aid nightly * diagnosed with insomnia or sleep apnea * history of delirium with opiates or zolpidem * allergic to opiates or zolpidem * had previous lumbar spine surgery * undergoing minimally invasive lumbar fusion, * undergoing lumbar fusion for fracture, infection, tumor, or an inflammatory spondyloarthropathy

Keywords: lumbar spine fusion zolpidem postoperative outcomes